Attached files

file filename
EX-99.1 - EX-99.1 - SCICLONE PHARMACEUTICALS INCd691639dex991.htm





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934.

Date of Report: March 12, 2014

(Date of earliest event reported)



SciClone Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)




Delaware   0-19825   94-3116852
(State or other jurisdiction
of incorporation)
File Number)
  (IRS Employer
Identification Number)
950 Tower Lane, Suite 900, Foster
City, CA
(Address of principal executive offices)     (Zip Code)

(650) 358-3456

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 2.02 Results of Operations and Financial Condition.

On March 12, 2014, SciClone Pharmaceuticals, Inc. issued a press release announcing final financial results for the fourth quarter and year ended December 31, 2013. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein in its entirety.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01 Financial Statements and Exhibits.


(d) The following exhibits are filed herewith:
Exhibit 99.1    Press release dated March 12, 2014.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: March 12, 2014     SCICLONE PHARMACEUTICALS, INC.
      By:   /s/ WILSON W. CHEUNG
        Wilson W. Cheung
        Chief Financial Officer and
        Senior Vice President, Finance

Exhibit Index


Exhibit No.



99.1    Press release dated March 12, 2014.